Webinars for Continuing Education
Basic Tutorials for Those New to the Use of Biomarkers
Accreditations (1 hour each): ACCME, ACCME-NP, ANCC, AOTA, APA, ASWB, JAIPCE, NYSED, NYSED-P (Need to create TRAIN account where you can access much more!)
Examining Diagnostic Approaches to Dementia Care Through Use of Biomarkers, Allyson Rosen and Suzanne Schindler, GRECC-Connect (through TRAIN)
Ethical and Practical Issues in Disclosure of Dementia Risk, Scott Roberts and Emily Largent, GRECC-Connect (through TRAIN)
Biofluid Based Biomarkers in Neuropsychiatric Syndromes Series
Accreditations: ACCME
The First Webinar, October 2021 (with Corinne Fischer & Rawan Tarawneh)
The Disparities Webinar, February 2022 (with Paulo Bertolucci & Ganesh Babulal)
The Metabolic Derangements Webinar, June 2022 (with George Perry & Ramit Ravona-Springer)
The Multi-Modal Biomarker Webinar, February 2023 (with Jennifer Gatchel & Fabio Porto)
The Alzheimer's Association has much more! (https://training.alz.org/ClinicalEducation)
Collaborative Publications
Member Publications
- Oliveira FF, Almeida SS, Chen ES, Smith MC, Bertolucci PHF (2022) APOE ε4 Carrier Status as Mediator of Effects of Psychotropic Drugs on Clinical Changes in Patients With Alzheimer's Disease. The Journal of Neuropsychiatry and Clinical Neurosciences 34, 351-360.
- del Campo M, Zetterberg H, Gandy S, Onyike CU, Oliveira F, Udeh-Momoh C, Lleó A, Teunissen CE, Pijnenburg Y (2022) New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. Alzheimer's & Dementia 18, 2292-2307.
- Erickson, Chin, Ketchum, Jonaitis, Zuelsdorff, Gleason, Clark. Predictors of Willingness to Enroll in Hypothetical Alzheimer Disease Biomarker Studies that Disclose Personal Results. Alzheimer Disease & Associated Disorders: February 04, 2022 - Volume - Issue - doi: 10.1097/WAD.0000000000000490
- Langlois CM, Bradbury A, Wood EM, Roberts JS, Kim SYH, Riviere M-E, Liu F, Reiman EM, Tariot PN, Karlawish J, Langbaum JB (2019) Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials. Alzheimer's & Dementia: Translational Research & Clinical Interventions 5, 705-716.
- Oliveira FF, Bertolucci PHF, Chen ES, Smith MC (2022) Pharmacogenetic Analyses of Therapeutic Effects of Lipophilic Statins on Cognitive and Functional Changes in Alzheimer's Disease. Journal of Alzheimer's Disease 87, 359-372.
- De Oliveira FF (2022) The Viability of Treatment Conditioned to the Pathophysiology of Alzheimer's Disease. In: Santos GAA. Pharmacological Treatment of Alzheimer's Disease: Scientific and Clinical Aspects. Springer, Cham, v. 1, pp. 31-52.
- Qian J, Wolters FJ, Beiser A, Haan M, Ikram MA, Karlawish J, Langbaum JB, Neuhaus JM, Reiman EM, Roberts JS, Seshadri S, Tariot PN, Woods BM, Betensky RA, Blacker D (2017) APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts. PLoS Med 14, e1002254.
- Schindler SE, Karikari TK, Ashton NJ, Henson RL, Yarasheski KE, West T, Meyer MR, Kirmess KM, Li Y, Saef B, Moulder KL, Bradford D, Fagan AM, Gordon BA, Benzinger TLS, Balls-Berry J, Bateman RJ, Xiong C, Zetterberg H, Blennow K, Morris JC. Effect of race on prediction of brain amyloidosis by plasma Aβ42/Aβ40, phosphorylated tau, and neurofilament light. Neurology. April 21, 2022. DOI: 10.1212/WNL.0000000000200358
- van der Schaar, J., Visser, L.N.C., Bouwman, F.H. et al. Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review. Alz Res Therapy 14, 31 (2022). https://doi.org/10.1186/s13195-022-00971-3